Agent Information
The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
Cemiplimab (REGN2810, Libtayo) is a humanized, hinge-stabilized, IgG4K monoclonal antibody (mAb) designed to target PD-1-expressing cells, including T cells, and sustain or restore their effector function by blocking checkpoint inhibitory interactions between PD-1 and its ligands (PD-L1 and PD-L2). It has received approval for the treatment of patients with metastatic or some locally advanced cutaneous squamous cell carcinomas.
REGN3767 is a fully human, hinge-stabilized IgG4 monoclonal antibody (mAb) that binds with high affinity to LAG-3 and blocks this pathway of inhibitory T-cell signaling.
Preclinical and preliminary clinical evidence has shown the combination of cemiplimab plus REGN3767 has antitumor activity can result in objective responses across several tumor types.
Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.
